Share Email Print
cover

Journal of Biomedical Optics • Open Access

Preclinical evidence of mitochondrial nicotinamide adenine dinucleotide as an effective alarm parameter under hypoxia

Paper Abstract

Early detection of tissue hypoxia in the intensive care unit is essential for effective treatment. Reduced nicotinamide adenine dinucleotide (NADH) has been suggested to be the most sensitive indicator of tissue oxygenation at the mitochondrial level. However, no experimental evidence comparing the kinetics of changes in NADH and other physiological parameters has been provided. The aim of this study is to obtain the missing data in a systematic and reliable manner. We constructed four acute hypoxia models, including hypoxic hypoxia, hypemic hypoxia, circulatory hypoxia, and histogenous hypoxia, and measured NADH fluorescence, tissue reflectance, cerebral blood flow, respiration, and electrocardiography simultaneously from the induction of hypoxia until death. We found that NADH was not always the first onset parameter responding to hypoxia. The order of responses was mainly affected by the cause of hypoxia. However, NADH reached its alarm level earlier than the other monitored parameters, ranging from several seconds to <10  min . As such, we suggest that the NADH can be used as a hypoxia indicator, although the exact level that should be used must be further investigated. When the NADH alarm is detected, the body still has a chance to recover if appropriate and timely treatment is provided.

Paper Details

Date Published: 27 January 2014
PDF: 7 pages
J. Biomed. Opt. 19(1) 017005 doi: 10.1117/1.JBO.19.1.017005
Published in: Journal of Biomedical Optics Volume 19, Issue 1
Show Author Affiliations
Hua Shi, Huazhong Univ. of Science and Technology (China)
Nannan Sun, Huazhong Univ. of Science and Technology (China)
Avraham Mayevsky, Wuhan National Lab. for Optoelectronics (China)
Zhihong Zhang, Britton Chance Ctr. for Biomedical Photonics (China)
Qingming Luo, Britton Chance Ctr. for Biomedical Photonics (China)


© SPIE. Terms of Use
Back to Top